Armed with positive phase 3 data, Venatorx Pharmaceuticals will ask regulators to approve its investigational combination antibiotic, cefepime-taniborbactam, as a treatment for complicated urinary tract infections (cUTI) in adults.
Source: Drug Industry Daily